What Therapeutic Class of Drugs Do You Think Dominated the Market in 2017?

Ogurchak: In 2017, I really don’t foresee there being any 1 therapeutic class that’s going to dominate the market like we saw with hep C over the last few years.

What we’re seeing is a number of new therapies coming to the market that often target novel sorts of conditions. So, where we used to see a large target for HIV or a large target for hep C, we’re likely going to see more and more therapies that are disjointed that don’t fall into a therapeutic class but it’s still providing a number of new opportunities to patients where there may not have been a solution otherwise.